{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T04:11:42Z","timestamp":1749615102412,"version":"3.41.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ajp.2025.104534","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T15:56:12Z","timestamp":1747410972000},"page":"104534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Truth or myth of minimum effective dose for patients with remitted psychosis: Implications from a guided dose reduction trial"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3527-5189","authenticated-orcid":false,"given":"Ko","family":"Yen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming H.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ling","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3821-4744","authenticated-orcid":false,"given":"Yi-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzung-Jeng","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-1940","authenticated-orcid":false,"given":"Chun-I.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9290-110X","authenticated-orcid":false,"given":"Chen-Chung","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2025.104534_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1017\/S0033291711001504","article-title":"Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years","volume":"42","author":"\u00c1lvarez-Jim\u00e9nez","year":"2012","journal-title":"Psychol. Med."},{"key":"10.1016\/j.ajp.2025.104534_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13063-019-3822-5","article-title":"To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction\/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial","volume":"21","author":"Begemann","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.ajp.2025.104534_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/schbul\/sbac138","article-title":"Risk factors for psychotic relapse after dose reduction or discontinuation of antipsychotics in patients with chronic schizophrenia. a meta-analysis of randomized controlled trials","volume":"49","author":"Bogers","year":"2023","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2025.104534_bib4","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Ceraso","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ajp.2025.104534_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jfma.2012.01.018","article-title":"Psychopathology, rehospitalization and quality of life among patients with schizophrenia under home care case management in Taiwan","volume":"112","author":"Chang","year":"2013","journal-title":"J. Formos. Med Assoc."},{"key":"10.1016\/j.ajp.2025.104534_bib6","first-page":"251","article-title":"Positive and negative syndrome scale (panss): establishment and reliability study of a mandarin Chinese language version","volume":"10","author":"Cheng","year":"1996","journal-title":"Chin. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218711","article-title":"Mental health professionals' views and experiences of antipsychotic reduction and discontinuation","volume":"14","author":"Cooper","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ajp.2025.104534_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12888-022-03822-5","article-title":"An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders","volume":"22","author":"Crellin","year":"2022","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/YCO.0000000000000940","article-title":"Gradually tapering off antipsychotics: lessons for practice from case studies and neurobiological principles","volume":"37","author":"Horowitz","year":"2024","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib11","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/schbul\/sbab017","article-title":"A method for tapering antipsychotic treatment that may minimize the risk of relapse","volume":"47","author":"Horowitz","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2025.104534_bib12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/eip.12765","article-title":"Psychiatrists' opinion towards medication discontinuation in remitted first-episode psychosis: a multi-site study of the Asian Network for Early Psychosis","volume":"13","author":"Hui","year":"2019","journal-title":"Early Inter. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/ijnp\/pyac002","article-title":"Guidelines for Discontinuation of Antipsychotics in Patients Who Recover From First-Episode Schizophrenia Spectrum Disorders: Derived From the Aggregated Opinions of Asian Network of Early Psychosis Experts and Literature Review","volume":"25","author":"Hui","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.ajp.2025.104534_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S2215-0366(18)30090-7","article-title":"Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial","volume":"5","author":"Hui","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/sbad112","article-title":"Addressing the evidence to practice gap: what to expect from international antipsychotic dose reduction studies in the tapering anti-psychotics and evaluating recovery consortium","volume":"50","author":"Koops","year":"2024","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2025.104534_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12888-018-1755-2","article-title":"Functional recovery in patients with schizophrenia: recommendations from a panel of experts","volume":"18","author":"Lahera","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","article-title":"Estimating dopamine D\u2082 receptor occupancy for doses of 8 antipsychotics: a meta-analysis","volume":"33","author":"Lako","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2025.104534_bib19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.ajp.2025.104534_bib20","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD Method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2025.104534_bib21","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/jamapsychiatry.2021.2130","article-title":"Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis","volume":"78","author":"Leucht","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12091362","article-title":"Racial\/ethnic differences in the pharmacokinetics of antipsychotics: focusing on east Asians","volume":"12","author":"Lin","year":"2022","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.ajp.2025.104534_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40263-019-00682-8","article-title":"Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm","volume":"34","author":"Liu","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ajp.2025.104534_bib24","article-title":"Challenging the minimum effective antipsychotic dose during maintenance: implications from 10-year follow-up of first episode psychosis","volume":"12","author":"Liu","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/eip.13144","article-title":"Protocol of guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis based on pragmatic design","volume":"16","author":"Liu","year":"2022","journal-title":"Early Inter. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib26","first-page":"1","article-title":"Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-year randomized controlled trial with a naturalistic cohort","author":"Liu","year":"2023","journal-title":"Psychol. Med"},{"key":"10.1016\/j.ajp.2025.104534_bib27","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2023.2440","article-title":"Dose-tapering trajectories in patients with remitted psychosis undergoing guided antipsychotic reduction to reach minimum effective dose","volume":"66","author":"Liu","year":"2023","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033291724002356","article-title":"Verification of successful maintenance by serum drug level during a guided antipsychotic reduction to reach minimum effective dose (GARMED) trial","volume":"54","author":"Liu","year":"2024","journal-title":"Psychol. Med"},{"key":"10.1016\/j.ajp.2025.104534_bib29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4088\/JCP.14m09540","article-title":"Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study","volume":"77","author":"Mayoral-van Son","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib30","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jamapsychiatry.2013.264","article-title":"Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more","volume":"70","author":"McGorry","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","article-title":"Association of anticholinergic load with impairment of complex attention and memory in schizophrenia","volume":"161","author":"Minzenberg","year":"2004","journal-title":"Am. J. Psychiatry"},{"year":"2008","series-title":"The Myth Of The Chemical Cure","author":"Moncrieff","key":"10.1016\/j.ajp.2025.104534_bib32"},{"key":"10.1016\/j.ajp.2025.104534_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030912","article-title":"Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)","volume":"9","author":"Moncrieff","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.ajp.2025.104534_bib34","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S2215-0366(23)00258-4","article-title":"Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial","volume":"10","author":"Moncrieff","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1192\/bjp.bp.116.182683","article-title":"Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?","volume":"209","author":"Murray","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3389\/fpsyt.2018.00447","article-title":"Dose reduction\/discontinuation of antipsychotic drugs in psychosis; effect on cognition and functional outcomes","volume":"9","author":"Omachi","year":"2018","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib37","first-page":"Cd014384","article-title":"Antipsychotic dose reduction compared to dose continuation for people with schizophrenia","volume":"11","author":"Rodolico","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ajp.2025.104534_bib38","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/schbul\/sbr189","article-title":"Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data","volume":"39","author":"Sakurai","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2025.104534_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.114383","article-title":"Effect of antipsychotic dose reduction on cognitive function in schizophrenia","volume":"308","author":"Singh","year":"2022","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.ajp.2025.104534_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.910703","article-title":"Tapered discontinuation vs. maintenance therapy of antipsychotic medication in patients with first-episode schizophrenia: obstacles, findings, and lessons learned in the terminated randomized clinical trial TAILOR","volume":"13","author":"St\u00fcrup","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib41","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/schbul\/sbt090","article-title":"Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study","volume":"39","author":"Takeuchi","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2025.104534_bib42","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/schbul\/sbaa063","article-title":"Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis","volume":"46","author":"Takeuchi","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2025.104534_bib43","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41386-019-0573-7","article-title":"Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials","volume":"45","author":"Tani","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ajp.2025.104534_bib44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/eip.12244","article-title":"Views of early psychosis clinicians on discontinuation of antipsychotic medication following symptom remission in first episode psychosis","volume":"10","author":"Thompson","year":"2016","journal-title":"Early Inter. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib45","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2018.17091001","article-title":"20-Year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia","author":"Tiihonen","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.schres.2010.01.021","article-title":"Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients","volume":"118","author":"Vernon","year":"2010","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.ajp.2025.104534_bib47","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/eip.12769","article-title":"Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol","volume":"13","author":"Weller","year":"2019","journal-title":"Early Inter. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2024.104172","article-title":"Long-term metabolic side effects of second-generation antipsychotics in Chinese patients with schizophrenia: A within-subject approach with modelling of dosage effects","volume":"100","author":"Wong","year":"2024","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.ajp.2025.104534_bib49","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.schres.2013.01.036","article-title":"Validation of the Taiwanese Mandarin version of the Personal and Social Performance scale in a sample of 655 stable schizophrenic patients","volume":"146","author":"Wu","year":"2013","journal-title":"Schizophr. Res"},{"key":"10.1016\/j.ajp.2025.104534_bib51","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ajp.2025.104534_bib52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2147\/NDT.S339866","article-title":"Discontinuing antipsychotic medication after remission from first-episode psychosis: a survey of psychiatrists' attitudes in Taiwan","volume":"18","author":"Yen","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ajp.2025.104534_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.euroneuro.2024.07.011","article-title":"The myth of minimum effective dose in antipsychotic treatment for patients with remitted psychosis","volume":"88","author":"Yen","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2025.104534_bib54","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/0269881118756062","article-title":"Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study","volume":"32","author":"Zhou","year":"2018","journal-title":"J. Psychopharmacol."}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201825001777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201825001777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T17:09:04Z","timestamp":1749575344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201825001777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":54,"alternative-id":["S1876201825001777"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2025.104534","relation":{},"ISSN":["1876-2018"],"issn-type":[{"type":"print","value":"1876-2018"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Truth or myth of minimum effective dose for patients with remitted psychosis: Implications from a guided dose reduction trial","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2025.104534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104534"}}